SCHEMBL2711296

SCHEMBL2711296

FC(F)(F)c1cc(N2CCNCC2)c2ccccc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 7/20 1.00
HTR6 P50406 4/20 0.70
ADRA2A P08913 1/20 0.70
HTR2C P28335 1/20 0.70
AXL P30530 1/20 0.70
HRH1 P35367 1/20 0.70
HTR2B P41595 1/20 0.70
MKNK1 Q9BUB5 1/20 0.70
MKNK2 Q9HBH9 1/20 0.70
NCF1 P14598 7/20 0.64
ADRB1 P08588 2/20 0.64
MAPK1 P28482 1/20 0.64
MAPT P10636 1/20 0.57
ALDH1A1 P00352 2/20 0.51
CYP1A2 P05177 2/20 0.51
KDM4E B2RXH2 1/20 0.51
HPGD P15428 1/20 0.50
ACVR1B P36896 1/20 0.49
TGFBR1 P36897 1/20 0.49
ACVRL1 P37023 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30058924 1.00 ADRB2 (1.00) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL2724231 0.95 ADRB2 (0.90) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL6595059 0.84 ADRB2 (0.73) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL2709564 0.84 ADRB2 (0.75) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL6125222 0.83 ADRB2 (0.72) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL425929 0.83 ADRB2 (0.71) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL2244546 0.83 ADRB2 (1.00) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL2708517 0.83 ADRB2 (0.73) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL23362148 0.81 ADRB2 (0.68) ADRB2HTR6ADRA2AHTR2CAXL
SCHEMBL30058841 0.81 ADRB2 (0.68) ADRB2HTR6ADRA2AHTR2CAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
US-12479821-B2 Quinoline compound and use thereof MBD Co., Ltd. (KR) 2025-11-25 US disclosed
US-20220402890-A1 NOVEL QUINOLINE COMPOUND AND USE THEREOF MBD CO., LTD (KR) 2022-12-22 US disclosed
US-20220402890-A1 NOVEL QUINOLINE COMPOUND AND USE THEREOF MBD CO., LTD (KR) 2022-12-22 US disclosed
WO-2022235091-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF 엠비디 주식회사 2022-11-10 WO disclosed
WO-2021096335-A1 NOVEL QUINOLINE COMPOUND AND USE THEREOF 엠비디 주식회사 2021-05-20 WO disclosed
WO-2021096335-A1 NOVEL QUINOLINE COMPOUND AND USE THEREOF 엠비디 주식회사 2021-05-20 WO disclosed
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN disclosed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US disclosed
US-6313126-B1 FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY AMERICAN HOME PRODUCTS CORP 2001-11-06 US disclosed
EP-1147083-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2001-10-24 EP disclosed
US-6207667-B1 USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-03-27 US disclosed
US-6169088-B1 FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-01-02 US disclosed
WO-2000040554-A1 ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 2000-07-13 WO disclosed
WO-1999031096-A1 PIPERAZINE DERIVATIVES USEFUL AS HYPOGLYCEMIC AGENTS SHAMAN PHARMACEUTICALS, INC. (US) 1999-06-24 WO disclosed
CN-1208404-A Nitrogenous heterocyclic compounds KYOWA HAKKO KOGYO KK (JP) 1999-02-17 CN disclosed
EP-0882717-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479821-B2 Quinoline compound and use thereof CYP4A11, CYP7A1, CYP4B1 ADRB2 1647/4885HTR6 3052/4885ADRA2A 1126/4885
US-20220402890-A1 NOVEL QUINOLINE COMPOUND AND USE THEREOF CYP4A11, CYP4B1, CYP4A22 ADRB2 1242/4885HTR6 2699/4885ADRA2A 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.